Correlation Between Histogen and Scopus Biopharma
Can any of the company-specific risk be diversified away by investing in both Histogen and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Histogen and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Histogen and Scopus Biopharma, you can compare the effects of market volatilities on Histogen and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Histogen with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Histogen and Scopus Biopharma.
Diversification Opportunities for Histogen and Scopus Biopharma
0.11 | Correlation Coefficient |
Average diversification
The 3 months correlation between Histogen and Scopus is 0.11. Overlapping area represents the amount of risk that can be diversified away by holding Histogen and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Histogen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Histogen are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Histogen i.e., Histogen and Scopus Biopharma go up and down completely randomly.
Pair Corralation between Histogen and Scopus Biopharma
If you would invest 10.00 in Scopus Biopharma on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Scopus Biopharma or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 1.56% |
Values | Daily Returns |
Histogen vs. Scopus Biopharma
Performance |
Timeline |
Histogen |
Scopus Biopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Histogen and Scopus Biopharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Histogen and Scopus Biopharma
The main advantage of trading using opposite Histogen and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Histogen position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.Histogen vs. Virax Biolabs Group | Histogen vs. Altamira Therapeutics | Histogen vs. Aileron Therapeutics | Histogen vs. Artelo Biosciences |
Scopus Biopharma vs. Scpharmaceuticals | Scopus Biopharma vs. DiaMedica Therapeutics | Scopus Biopharma vs. Monopar Therapeutics | Scopus Biopharma vs. Pasithea Therapeutics Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Complementary Tools
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |